Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.

Literature DB >> 24048329

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.

Mario Sznol¹, Lieping Chen.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 24048329 PMCID： PMC6101650 DOI： 10.1158/1078-0432.CCR-13-2234

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

× No keyword cloud information.

2 in total

1. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors: Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal: Nat Med Date: 2002-06-24 Impact factor: 53.440

2. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

2 in total

45 in total

1. Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.

Authors: Rojan Shrestha; Sarah C Garrett; Steven C Almo; Andras Fiser
Journal: Structure Date: 2019-03-28 Impact factor: 5.006

Review 2. PD-1/PD-L1 inhibitors.

Authors: Joel Sunshine; Janis M Taube
Journal: Curr Opin Pharmacol Date: 2015-06-02 Impact factor: 5.547

Review 3. Predictive factors for immunotherapy in melanoma.

Authors: Cristina Teixidó; Maria González-Cao; Niki Karachaliou; Rafael Rosell
Journal: Ann Transl Med Date: 2015-09

Review 4. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Authors: Maria Romina Girotti; Grazia Saturno; Paul Lorigan; Richard Marais
Journal: Mol Oncol Date: 2014-08-15 Impact factor: 6.603

5. Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

Authors: Franz Villarroel-Espindola; Xiaoqing Yu; Ila Datar; Nikita Mani; Miguel Sanmamed; Vamsidhar Velcheti; Konstantinos Syrigos; Maria Toki; Hongyu Zhao; Lieping Chen; Roy S Herbst; Kurt A Schalper
Journal: Clin Cancer Res Date: 2017-12-04 Impact factor: 12.531

6. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.

Authors: Xiuyun Lin; Tao Zeng; Jinxiang Lin; Qiong Zhang; Haoling Cheng; Shubin Fang; Shuchun Lin; Yuanzhong Chen; Yunlu Xu; Jizhen Lin
Journal: Cancer Biol Ther Date: 2019-11-06 Impact factor: 4.742

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.

1. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

2. Nivolumab plus ipilimumab in advanced melanoma.

1. Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.

Review 2. PD-1/PD-L1 inhibitors.

Review 3. Predictive factors for immunotherapy in melanoma.

Review 4. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

5. Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

6. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.

7. The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy.

Review 8. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.

Review 9. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.

10. Myeloid cells' evasion of melanoma immunity.